Cantor Fitzgerald starts Ensysce Biosciences with Overweight and $2 target
Cantor Fitzgerald rates Ensysce Biosciences Overweight with a $2 price target, against an October 19 close of $0.50, according to TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Analysts at Cantor Fitzgerald have begun covering Ensysce Biosciences shares, assigning an Overweight rating and a $2.00 price target. According to TradingView, that target implies an upside of about 297.7% from the October 19 close of $0.50.
The analyst note says the CY200 formulation aims to provide lasting pain relief for chronic pain, particularly persistent or refractory Complex Regional Pain Syndrome. It is built on psilocybin's neuroplasticity effects, which the analysts believe could last beyond the acute psychedelic experience. Initial patient data showed a 50% responder rate. The analysts argue that if an upcoming phase 2 trial confirms efficacy and durability, the current market capitalization may be too low.
why it matters
For markets this is a routine event: a single analyst rating on a small company trading near $0.50. The target sits well above the current price, but the outcome depends largely on phase 2 clinical data. The stock remains speculative, and its direction will be driven by trial results rather than one rating.
tags
instruments
sources
- Cantor Fitzgerald initiates coverage of Ensysce Biosciences with Overweight rating, $2 price target — TradingView, 20 October 2026 at 10:48 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗